TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31352029

Group type: EXPERIMENTAL
Intervention: Active ABM training shifting attention away from threat
Number of subjects: 32

Group type: COMPARATOR
Intervention: Attention control training involving no attention modification
Number of subjects: 32
Study: 29211950

Group type: EXPERIMENTAL
Intervention: 67% NaHCO3 plus 1425 ppm fluoride (F) as sodium fluoride (NaF)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 45% NaHCO3 plus 1425 ppm fluoride (F) as sodium fluoride (NaF)
Number of subjects: 115

Group type: COMPARATOR
Intervention: 0% NaHCO3 plus silica and 1450 ppm fluoride (F) as sodium fluoride (NaF)
Number of subjects: 115

Group type: COMPARATOR
Intervention: 0% NaHCO3 plus silica and 1400 ppm fluoride (F) as amine F/stannous F
Number of subjects: 115

Group type: COMPARATOR
Intervention: 0% NaHCO3 plus chlorhexidine/aluminum lactate and silica with 1360 ppm fluoride (F) as aluminum F
Number of subjects: 115
Study: 25733317

Group type: EXPERIMENTAL
Intervention: ivabradine (10-15 mg/day for 6 months)
Number of subjects: 98
Study: 23540545

Group type: EXPERIMENTAL
Intervention: Rhythm control arm (n = 128)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Rate control arm (n = 2,027)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Rhythm control arm without PM (n = 1,905)
Number of subjects: 250
Study: 21700416

Group type: EXPERIMENTAL
Intervention: Eco‐CIMT for 2h a day over a period of two months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control period (ordinary treatment)
Number of subjects: 25
Study: 19565732

Group type: EXPERIMENTAL
Intervention: Acupoint application of Chinese medicine at Dazhui (GV 14), Feishu (BL 13), Gaohuang (BL 43), Danzhong (CV 17), Qihai (CV 6)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine acupuncture at Zhongfu (LU 1), Tiantu (CV 22), Danzhong (CV 17), Dingchuan (EX‐B 1), Fenglong (ST 40)
Number of subjects: 100
Study: 16890688

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15017450

Group type: EXPERIMENTAL
Intervention: Telephone social support and education over a 12-month period
Number of subjects: 17

Group type: COMPARATOR
Intervention: Education through mailed resource kits only (Control)
Number of subjects: 17
Study: 11373411

Group type: EXPERIMENTAL
Intervention: Lenercept (0.125 mg/kg intravenous)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1342
Study: 9266384

Group type: EXPERIMENTAL
Intervention: New amino acid formulation and treatment products
Number of subjects: 25
Study: 8518240

Group type: EXPERIMENTAL
Intervention: Antepartum X-ray pelvimetry (XRP) at 36 weeks gestation
Number of subjects: 306

Group type: COMPARATOR
Intervention: Trial labour without antepartum XRP (Control)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Adequate antepartum XRP
Number of subjects: 306

Group type: COMPARATOR
Intervention: Inadequate postpartum XRP in control group
Number of subjects: 306

Group type: COMPARATOR
Intervention: Adequate postpartum XRP in control group
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Birthweight of infants
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Maternal morbidity
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Neonatal morbidity
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Maternal and perinatal mortality
Number of subjects: 306
Study: 3319111

Group type: EXPERIMENTAL
Intervention: Reduced sodium diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal salt diet
Number of subjects: 100
Study: 29505812

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 104
Study: 27582287

Group type: EXPERIMENTAL
Intervention: Bimaxillary orthognathic surgery (Le Fort I osteotomy and mandibular setback)
Number of subjects: 20
Study: 24737678

Group type: EXPERIMENTAL
Intervention: Thioguanine treatment arm (CCG‐1952 clinical trial)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Combination of MTHFR and TPMT variant genotypes
Number of subjects: 351
Study: 22420475

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine (1 mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (1 mL)
Number of subjects: 90
Study: 20709127

Group type: EXPERIMENTAL
Intervention: Participants who ate in the dark with super-size portions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Participants who ate in the dark with regular portions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (ate the same meal in the light)
Number of subjects: 64
Study: 18853588

Group type: EXPERIMENTAL
Intervention: Nasal Prongs (NP)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Oxygen (NPO)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Facemask (FM)
Number of subjects: 37
Study: 15683110

Group type: EXPERIMENTAL
Intervention: ReoPro-coated stent
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 155
Study: 11429337

Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion at 1.3 +/- 0.4 microg.kg(-1).min(-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Concurrent infusion of phenylephrine
Number of subjects: 9
Study: 9531030

Group type: EXPERIMENTAL
Intervention: Prothrombin fragment 1+2 (F1+2) assay
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Thrombin antithrombin III complexes (TAT) assay
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: D-dimer assay
Number of subjects: 159

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU t.i.d.)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Desirudin (10, 15 or 20 mg b.i.d.)
Number of subjects: 159
Study: 8602905

Group type: EXPERIMENTAL
Intervention: Platinum dentifrice (1.3% soluble pyrophosphate and 1.5% copolymer)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Crest Tartar Control dentifrice (5% soluble pyrophosphate)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Low abrasive dentifrice
Number of subjects: 85
Study: 2737311

Group type: EXPERIMENTAL
Intervention: Intramuscular analgesics given at fixed hours (methadone 10 mg i.m. every 12 h for days 1-3; sodium diclofenac 75 mg i.m. every 12 h for days 4-7)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intramuscular analgesics given at fixed hours
Number of subjects: 35

Group type: COMPARATOR
Intervention: Drugs 'on demand' or not treated at all
Number of subjects: 35
Study: 342618

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 virus vaccines (200, 400, or 800 chick cell-agglutinating units)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 virus vaccines (all dosages)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 virus vaccines
Number of subjects: 199
Study: 30472196

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels < 45 ng/L
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels (continuous variable)
Number of subjects: 120
Study: 28683017

Group type: EXPERIMENTAL
Intervention: Simulation training (1-hour PowerPoint presentation and video)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Traditional training (PowerPoint presentation and video showing traditional demonstration)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 69
Study: 25735317

Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) added to standard chemotherapy (CT)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Standard chemotherapy (CT) only
Number of subjects: 376
Study: 24968500

Group type: EXPERIMENTAL
Intervention: Injection lignocaine (preservative free) 1.5 mg/kg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral pregabalin 150 mg capsule
Number of subjects: 60
Study: 21300952

Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 9166

Group type: COMPARATOR
Intervention: Delayed provisional use of eptifibatide
Number of subjects: 9166
Study: 19233341

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg every other day)
Number of subjects: 22071

Group type: EXPERIMENTAL
Intervention: Any aspirin use (self-selected)
Number of subjects: 22071
Study: 16520405

Group type: EXPERIMENTAL
Intervention: Hemodynamic arm (impedance cardiography)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 164
Study: 14708242

Group type: EXPERIMENTAL
Intervention: Gentos
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 11571919

Group type: EXPERIMENTAL
Intervention: Aluminum splints
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Steel splints
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 33
Study: 9290024

Group type: EXPERIMENTAL
Intervention: Early alterations observed if acute renal failure (ARF) lasted for 1-10 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Late kidney alterations observed if ARF lasted for 11-20 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Delayed alterations observed if ARF lasted for 21-62 days
Number of subjects: 64
Study: 8080611

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 micrograms BD for eight weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment for four weeks
Number of subjects: 14
Study: 2947537

Group type: EXPERIMENTAL
Intervention: Cefoperazone 0.5 g
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cefoperazone 1.0 g
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Spectinomycin 2.0 g
Number of subjects: 204
Study: 30569984

Group type: EXPERIMENTAL
Intervention: CrCo-Ti rods
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ti-Ti rods
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both rod types
Number of subjects: 59
Study: 27881338

Group type: EXPERIMENTAL
Intervention: Guifu Dihuang Wan (GFDHW) with lifestyle intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (lifestyle intervention only)
Number of subjects: 62
Study: 24411805

Group type: EXPERIMENTAL
Intervention: Alcohol (target breath alcohol concentration of 0.08%)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 24312450

Group type: EXPERIMENTAL
Intervention: Lymphocyte-predominant breast cancer (LPBC)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Stromal lymphocytes (strLy)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Intratumoral lymphocytes (iTuLy)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Non-LPBC patients
Number of subjects: 313
Study: 20299470

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery-induced weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosiglitazone (peroxisome proliferator-activated receptor agonist)
Number of subjects: 0
Study: 19092464

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 1610
Study: 16099089

Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 0
Study: 12942405

Group type: EXPERIMENTAL
Intervention: Advice Accepted (AA) - regimens recommended by the expert panel
Number of subjects: 74

Group type: COMPARATOR
Intervention: Advice Rejected (AR) - regimens per clinician's preference
Number of subjects: 74
Study: 10640260

Group type: EXPERIMENTAL
Intervention: 2.5 mg zolmitriptan
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study: 8887580

Group type: EXPERIMENTAL
Intervention: Oral mexiletine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1889254

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3932077

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29499792

Group type: EXPERIMENTAL
Intervention: ISI‐Math
Number of subjects: 370

Group type: COMPARATOR
Intervention: ISI‐Reading
Number of subjects: 370
Study: 26642301

Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 24599353

Group type: EXPERIMENTAL
Intervention: No-touch isolation pancreaticoduodenectomy (NT-PD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy (ST-PD)
Number of subjects: 12
Study: 22688828

Group type: EXPERIMENTAL
Intervention: SLC22A12 SNP rs11602903
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: SLC22A12 SNP rs505802
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: SLC22A12 SNP rs11231825
Number of subjects: 414

Group type: COMPARATOR
Intervention: SLC22A12 SNP rs11602903 in African Americans
Number of subjects: 414
Study: 20531245

Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 U intravenously before ERCP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Gabexate
Number of subjects: 7
Study: 18541561

Group type: EXPERIMENTAL
Intervention: Sesame oil muffin consumption (sesamin, 94 mg; sesamolin, 42 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Corn oil muffin consumption
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sesame oil muffin consumption
Number of subjects: 10
Study: 17570961

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Active social support procedure
Number of subjects: 58
Study: 15325678

Group type: EXPERIMENTAL
Intervention: Diet containing 10.4 g/d of fiber
Number of subjects: 56

Group type: COMPARATOR
Intervention: Diet containing 30.5 g/d of fiber
Number of subjects: 56
Study: 11314452

Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 250

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 250
Study: 9287967

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 75
Study: 8394061

Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg once a day for 6 consecutive days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no antiemetic treatment)
Number of subjects: 52
Study: 2872260

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 238

Group type: COMPARATOR
Intervention: Hospital outpatient management
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Treatment phase completion
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Duration of current episodes of back pain
Number of subjects: 238
Study: 31640711

Group type: EXPERIMENTAL
Intervention: ICT+CCRT
Number of subjects: 502

Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Additional ICT
Number of subjects: 502
Study: 29238506

Group type: EXPERIMENTAL
Intervention: Gabapentin, titrated from 300 mg/day to a maximum of 900 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topiramate, titrated from 50 mg/day to a maximum of 100 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 30
Study: 25494032

Group type: EXPERIMENTAL
Intervention: Sodium phosphate supplementation (50 mg · kg·fat‐free‐mass⁻¹ · day⁻¹; n = 7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 17
Study: 23855591

Group type: EXPERIMENTAL
Intervention: Standardized physical therapy program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular physical therapy
Number of subjects: 100
Study: 21692299

Group type: EXPERIMENTAL
Intervention: Group A (compound general anesthesia with meridian points)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (compound general anesthesia with placebo points)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (general anesthesia only)
Number of subjects: 90
Study: 19539097

Group type: COMPARATOR
Intervention: Zoledronate
Number of subjects: 4163

Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 4163

Group type: COMPARATOR
Intervention: Clodronate
Number of subjects: 4163

Group type: COMPARATOR
Intervention: Clodronate, pamidronate, and zoledronate
Number of subjects: 4163
Study: 16818530

Group type: EXPERIMENTAL
Intervention: Open-loop feedback plus reinforcement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open-loop feedback alone (Control)
Number of subjects: 30
Study: 12615634

Group type: EXPERIMENTAL
Intervention: Repeated 6-minute walk test
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Continuous (circular or oval) walking course
Number of subjects: 761

Group type: COMPARATOR
Intervention: Straight (out and back) walking course
Number of subjects: 761
Study: 10684705

Group type: EXPERIMENTAL
Intervention: Paclitaxel-containing chemotherapy
Number of subjects: 53
Study: 9373687

Group type: EXPERIMENTAL
Intervention: Higher-order stereoscopic motion (higher-order SM) under correlated conditions with long ISI (ISI > 73 msec)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-order stereoscopic motion (higher-order SM) under uncorrelated conditions with zero ISI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-order stereoscopic motion (higher-order SM) with large distance of dot jump or varied directions of dots' motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local first-order motion signals weakened by appropriate temporal and spatial conditions or by incoherent motion directions
Number of subjects: 0
Study: 8360132

Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg bd
Number of subjects: 662

Group type: COMPARATOR
Intervention: Doxycycline 200 mg for the first dose followed by 100 mg od
Number of subjects: 662

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 662
Study: 3739357

Group type: EXPERIMENTAL
Intervention: 240 mg theophyllinethylendiamine (Euphyllin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined medication consisting of 25 mg theophyllin, 85 mg etophyllin, 30 mg papaverine and 0.1 mg atropine methylnitrate (Perphyllon)
Number of subjects: 20
Study: 30407744

Group type: EXPERIMENTAL
Intervention: Needle-free jet (MadaJet)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Needle injection
Number of subjects: 59
Study: 29995326

Group type: EXPERIMENTAL
Intervention: CDI + booster email
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: CDI-only
Number of subjects: 537

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 537
Study: 26939115

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 140

Group type: COMPARATOR
Intervention: Manual SICS
Number of subjects: 140
Study: 24702786

Group type: EXPERIMENTAL
Intervention: Comprehensive mental intervention (support, counselling, music, massage plus conventional therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy (three‐cavity gastric tube, fasting, parenteral/enteral nutrition, routine care, health guidance)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comprehensive mental intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 120
Study: 22691658

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ORIF
Number of subjects: 60
Study: 19856237

Group type: EXPERIMENTAL
Intervention: Structured training program in psychotherapeutic skills
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 170
Study: 17658101

Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of a placebo medication and preincision local infiltration of 40 mL of 0.5 per cent bupivicaine at trocar sites
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of 50 mg of rofecoxib
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Preoperative oral administration of 50 mg of rofecoxib and preincision local infiltration of 40 mL of 0.5 per cent bupivicaine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Preoperative oral administration of a placebo medication
Number of subjects: 55
Study: 16061594

Group type: EXPERIMENTAL
Intervention: Infasurf (calfactant)
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Survanta (beractant)
Number of subjects: 2110
Study: 11470697

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 27

Group type: COMPARATOR
Intervention: timolol gel 0.5%
Number of subjects: 27
Study: 10085699

Group type: EXPERIMENTAL
Intervention: Basic neurological examination, conduction velocities in the sural and tibial nerves, R-R interval variation, sympathetic skin response
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: R-R interval variation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Duration of nephropathy, duration of renal treatment, duration of dialysis treatment
Number of subjects: 51
Study: 7921444

Group type: EXPERIMENTAL
Intervention: Nasal challenge with human recombinant IL-8
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 19
Study: 2842403

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 31748125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1723
Study: 28963853

Group type: EXPERIMENTAL
Intervention: LETS ACT (n = 142)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Supportive Counseling (SC; n = 121)
Number of subjects: 263
Study: 26289723

Group type: EXPERIMENTAL
Intervention: 24-week telerehabilitation programme in addition to conventional cardiac rehabilitation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation alone
Number of subjects: 140